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Abstract
OBJECTIVES: To evaluate the efficacy and safety of subcutaneous golimumab
as add-on therapy in patients with active rheumatoid arthritis (RA) despite
disease-modifying antirheumatic drug (DMARD) treatment. To evaluate an
intravenous plus subcutaneous (IV+SC) golimumab strategy in patients who had
not attained remission. METHODS: GO-MORE was an open-label, multinational,
prospective study in patients with active RA in typical clinical practice settings.
In part 1, patients received add-on monthly 50-mg subcutaneous golimumab
for 6 months. The percentage of patients with good/moderate European
League Against Rheumatism (EULAR) 28-joint disease activity score (DAS28)-
erythrocyte sedimentation rate (ESR) response was compared in patient
subgroups with various concurrent or previous DMARD treatments. In part 2,
patients with EULAR responses but not remission were randomly assigned to
receive IV+SC or subcutaneous golimumab to month 12; DAS28-ESR remission
was measured. RESULTS: 3366 pat...
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ABSTRACT
Objectives To evaluate the efﬁcacy and safety of
subcutaneous golimumab as add-on therapy in patients
with active rheumatoid arthritis (RA) despite disease-
modifying antirheumatic drug (DMARD) treatment. To
evaluate an intravenous plus subcutaneous (IV+SC)
golimumab strategy in patients who had not attained
remission.
Methods GO-MORE was an open-label, multinational,
prospective study in patients with active RA in typical
clinical practice settings. In part 1, patients received add-
on monthly 50-mg subcutaneous golimumab for
6 months. The percentage of patients with good/
moderate European League Against Rheumatism
(EULAR) 28-joint disease activity score (DAS28)–
erythrocyte sedimentation rate (ESR) response was
compared in patient subgroups with various concurrent
or previous DMARD treatments. In part 2, patients with
EULAR responses but not remission were randomly
assigned to receive IV+SC or subcutaneous golimumab
to month 12; DAS28–ESR remission was measured.
Results 3366 patients were enrolled. At baseline of
part 1, 3280 efﬁcacy-evaluable patients had mean
disease duration of 7.6 years and mean DAS28–ESR of
5.97 (SD=1.095). At month 6, 82.1% achieved good/
moderate EULAR responses and 23.9% attained
remission. When EULAR responses were analysed by the
number of previously failed DMARD or the concomitant
methotrexate dose, DMARD type, or corticosteroid use,
no statistically signiﬁcant differences were observed.
Part 2 patients (N=490) who received IV+SC or
subcutaneous golimumab achieved similar remission
rates (∼25%). Adverse events were consistent with
previous reports of golimumab and other tumour
necrosis antagonists in this population.
Conclusions Add-on monthly subcutaneous
golimumab resulted in good/moderate EULAR response
in most patients; 25% achieved remission after 6 more
months of golimumab, but an IV+SC regimen provided
no additional efﬁcacy over the subcutaneous regimen.
INTRODUCTION
Evidence-based clinical practice guidelines and
consensus statements on the use of biological
agents in rheumatoid arthritis (RA) recommend
the use of tumour necrosis factor (TNF)α inhibi-
tors for patients with RA in whom therapy with
conventional disease-modifying antirheumatic
drugs (DMARD), including methotrexate, has
failed.1 2 International guidelines also recommend
that the primary target of RA management should
be to achieve and maintain clinical remission or
at least a state of low disease activity, thereby
preventing progression of joint damage and
disability.1 3 4
In placebo-controlled clinical trials of RA, goli-
mumab, an anti-TNFα monoclonal antibody, has
demonstrated clinical efﬁcacy in methotrexate-naive
patients, patients with previous inadequate metho-
trexate response, and patients with previous experi-
ence with at least one other TNF inhibitor.5–10 In
the placebo-controlled GO-FORWARD trial,
patients with active RA despite methotrexate treat-
ment improved on multiple outcome measures
after receiving subcutaneous golimumab.6 In
GO-FURTHER, also a study of patients with active
RA despite methotrexate treatment, intravenous
golimumab plus methotrexate led to better out-
comes than placebo plus methotrexate as early as
week 2.11 Golimumab has also been shown to
inhibit radiographic progression in methotrexate-
naive patients.12
Limited information is available regarding the
efﬁcacy of golimumab in broad, heterogeneous
patient populations outside the clinical trial setting,
particularly as add-on therapy to various conven-
tional DMARD and to low doses of methotrexate
(<15 mg/week). Gaining information about TNF
inhibitor responses among RA patients with a range
of concomitant medications and treatment histories
has the potential to improve treatment strategies,
especially as the use of TNF inhibitors becomes
more widespread and treatment goals evolve. In
addition, no studies have evaluated the potential
beneﬁt of using a complementary intravenous plus
subcutaneous (IV+SC) strategy to increase the
chances of achieving remission. Strategies that
target remission as the goal of therapy have shown
improved overall disease control,13 and the higher
drug exposure and weight-based dosing of an intra-
venous regimen may make it useful for attaining
remission.14–16
Here we report the results of the GO-MORE
trial, a two-part study that investigated the use of
golimumab as add-on therapy for RA patients who
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were receiving a variety of concomitant DMARD in typical clin-
ical practice settings. Part 2 evaluated whether an IV+SC goli-
mumab treatment strategy might boost the efﬁcacy of the initial
subcutaneous regimen in patients who achieved response but
not remission in part 1.
METHODS
Design and procedures
GO-MORE was an open-label, multinational (40 countries, 475
centres), prospective trial (protocol P06129; NCT00975130)
composed of two parts (ﬁgure 1). The study received approval
Figure 1 Study design of GO-MORE parts 1 and 2 (A) and details of part 2 (B). DAS28, 28-joint disease activity score; ESR, erythrocyte
sedimentation rate; EULAR, European League Against Rheumatism; GLM, golimumab; IV, intravenous; IV golimumab2, IV golimumab 2 mg/kg;
SC, subcutaneous. aA ﬂare was deﬁned as DAS28–ESR of 2.6 or greater (not retaining remission).
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from appropriate research ethics committees and was conducted
in accordance with the Declaration of Helsinki and standards of
good clinical research practice. Data were collected from
29 October 2009 to 21 July 2011. Enrolled patients received
subcutaneous golimumab 50 mg administered by autoinjector
on the same day every month for 6 months. Patients continued
their current DMARD regimen and oral corticosteroid regimens
(if applicable) at stable doses. Assessments were performed at
scheduled visits (screening; baseline; start of month 2; start of
month 4; and end of month 6). Golimumab doses were admi-
nistered after efﬁcacy assessments.
In part 2, patients who had achieved a good or moderate
European League Against Rheumatism (EULAR) response, cal-
culated using the 28-joint disease activity score (DAS28) based
on erythrocyte sedimentation rate (ESR), but who were not in
remission (deﬁned as DAS28–ESR<2.6) at the end of month 6
were randomly assigned (1:1) to one of two treatment arms:
combination regimen of intravenous golimumab 2 mg/kg plus
subcutaneous golimumab 50 mg or continued subcutaneous
golimumab 50 mg. Details of the treatment regimens are shown
in ﬁgure 1. After eligibility was conﬁrmed, treatment assignment
was made by a central randomisation system. Randomisation
was stratiﬁed by concomitant DMARD regimen (including the
use of methotrexate or not) and disease activity at the start of
part 2 (DAS28–ESR <3.2 or DAS28–ESR≥3.2).
Patients
Patients were biological agent naive and had active RA despite
DMARD therapy. Key part 1 inclusion criteria included: age
18 years or older; an RA diagnosis according to the 1987
revised American College of Rheumatology criteria; active
disease (DAS28–ESR≥3.2) despite DMARD treatment; the use
of at least one allowable DMARD (methotrexate, sulfasalazine,
hydroxychloroquine, chloroquine, chloroquine phosphate, leﬂu-
nomide, gold salts, azathioprine and cyclosporine) at a stable
dose for at least 1 month before trial entry; and eligibility for
TNF inhibitor use according to local guidelines and the investi-
gator’s opinion.
Patients were excluded for: evidence of active tuberculosis or
untreated latent tuberculosis; a history of moderate to severe
heart failure; a history of lymphoproliferative disease or malig-
nancy within the past 5 years (except non-melanoma skin
cancer treated without recurrence); or any contraindication for
TNF inhibitor use. To be included in part 2, there must have
been no safety concerns that precluded additional exposure to
golimumab.
Efﬁcacy and safety measures
The primary efﬁcacy variable in part 1 was the proportion of
patients who achieved good/moderate EULAR response (deﬁned
as DAS28–ESR improvement of >1.2 from any baseline score or
an improvement of 0.6–1.2 from a baseline score of ≤5.1) at the
end of month 6. Key secondary efﬁcacy variables included several
composite measures of disease activity and their components:
DAS28 calculated with C-reactive protein (CRP), DAS28–ESR and
the simpliﬁed disease activity index (SDAI).17 Low disease activity
(DAS28–ESR and DAS28–CRP≤3.2, SDAI≤11), remission
(DAS28–ESR and DAS28–CRP<2.6, SDAI≤3.3), and achieve-
ment of minimal or no functional impairment (health assessment
questionnaire–disability index (HAQ–DI) ≤0.5) were also
assessed.
In part 2, the co-primary efﬁcacy measures were the propor-
tion of patients who were in DAS28–ESR remission at the start
of month 11 and the end of month 12. Key secondary
endpoints include normalised area under the curve (AUC) for
DAS28–ESR between the end of month 6 and the end of month
12 (AUC divided by the duration of time over which AUC is cal-
culated); time to DAS28–ESR remission; DAS28–ESR remission
rates; and proportion of patients achieving low disease activity
(DAS28–ESR and SDAI criteria).
Safety was assessed by collection of treatment-emergent
adverse events (TEAE).
Statistical methods
In part 1, enrolment of 3150 patients was planned for the
detection of small differences in EULAR response between treat-
ment subgroups. In part 2, a sample size of 500 with a 10%
dropout rate provided 90% power for a χ2 test to detect a 15%
treatment group difference in DAS28–ESR remission rate at
months 11 or 12 at an α level of 2.5% for each test.
The efﬁcacy-evaluable populations for part 1 and part 2
included patients who received one or more dose of golimumab
and had DAS28–ESR scores at baseline and at one or more post-
baseline visit in part 1 and part 2, respectively. The safety popula-
tions for part 1 and part 2 included all patients who received one
or more dose of study medication in part 1 and part 2, respectively.
In part 1, the primary outcome of good/moderate EULAR
response at month 6 was evaluated by several treatment vari-
ables: concomitant methotrexate dose (low (<10 mg/week),
medium (≥10 and <15 mg/week), high (≥15 mg/week)), con-
comitant corticosteroid use (yes or no), number of failed
DMARD (one, two, or three or more), and type of concomitant
DMARD (as shown in table 1). Cochran–Mantel–Haenszel
(CMH) χ2 tests were used to evaluate effects of treatment vari-
ables, controlling for baseline disease activity, with α of 0.05.
For response variables, missing values were treated as non-
response; other values were not imputed. For key secondary
efﬁcacy outcomes, analysis of covariance (ANCOVA) or logistic
ANCOVAwas used, with baseline scores as covariates.
Some analyses were also performed post-hoc for the subset of
patients who received concomitant methotrexate and those who
received leﬂunomide.
In part 2, the co-primary efﬁcacy measures were analysed with
χ2 tests with α of 0.025. Treatment group differences in normal-
ised AUC for DAS28–ESR and other continuous secondary end-
points were analysed using ANCOVA, adjusting for part 2
baseline scores. Time to remission was analysed using the
Kaplan–Meier method with log-rank tests.
RESULTS
Patient disposition and baseline characteristics
Figure 2 shows the disposition of patients in parts 1 and 2 of
the study. Characteristics of the efﬁcacy-evaluable population
(N=3280) are shown in table 1. In part 1, 90.9% (2981/3280)
of efﬁcacy-evaluable patients completed six golimumab doses
and 95.9% of those patients received doses on average every
28–33 days.
In part 2, baseline characteristics were similar in the IV+SC
golimumab and subcutaneous golimumab groups (table 1).
Efﬁcacy results
Part 1
After 6 months of golimumab treatment, 82.07% (2692/3280)
of patients had achieved a good/moderate EULAR response
(ﬁgure 3): 35.98% (1180/3280) achieved good response and
46.10% (1512/3280) achieved moderate response. When
EULAR responses were analysed by the number of previously
failed DMARD or the concomitant treatment variables of
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methotrexate dose, DMARD type, or corticosteroid use, no stat-
istically signiﬁcant pairwise differences were observed. Good/
moderate EULAR responses were achieved by approximately
80% of the patients across all subgroups (ﬁgure 3 and see sup-
plementary ﬁgure S1, available online only). Similarly, in ana-
lyses of effects of the treatment variables on DAS28–ESR,
DAS28–CRP and SDAI response rates (both changes from base-
line and mean values across visits), no clinically or statistically
signiﬁcant differences were found across the treatment sub-
groups (data not shown).
Good/moderate EULAR response and DAS–ESR low disease
activity and remission rates increased steadily over the 6-month
Table 1 Demographics and baseline characteristics
Patient characteristics: part 1 Subcutaneous golimumab (N=3280)
Demographic characteristics
Female, n (%) 2716 (82.8%)
Age, years
Mean (SD) 52.3 (12.8)
Median (min, max) 53.0 (18, 88)
Race, n (%)
White 2283 (69.6)
Multiracial 444 (13.5)
Other 211 (6.4)
Asian 167 (5.1)
Not allowed to collect these data 97 (3.0)
Black or African American 57 (1.7)
American Indian or Alaska Native 21 (0.6)
BMI (kg/m2), median (min, max) 26.2 (14.0, 54.5)
Treatment history
Concomitant methotrexate dose n=3280
Any dose, n (%) 2663 (81.2)
Low (<10 mg/week), n (%) 142 (4.3)
Medium (≥10 and <15 mg/week), n (%) 526 (16.0)
High (≥15 mg/week), n (%) 1995 (60.8)
Concomitant corticosteroid use n=3280
Received corticosteroids, n (%) 2078 (63.4)
DMARD combinations n=3270
Methotrexate only, n (%) 1681 (51.4)
Methotrexate+hydroxychloroquine, chloroquine, chloroquine phosphate, n (%) 433 (13.2)
Methotrexate+leflunomide, n (%) 216 (6.6)
Methotrexate+sulfasalazine, n (%) 150 (4.6)
Methotrexate+hydroxychloroquine, chloroquine, chloroquine phosphate+sulfasalazine, n (%) 106 (3.2)
Leflunomide only, n (%) 303 (9.3)
Other DMARD combinations,* n (%) 381 (11.7)
No of DMARD failed n=3279
1, n (%) 1129 (34.4)
2, n (%) 1176 (35.9)
≥3, n (%) 974 (29.7)
Disease characteristics
Disease duration, years n=3279
Mean (SD) 7.6 (7.9)
Median (min, max) 4.9 (0.01, 56.6)
TJC28, mean (SD) 13.0 (6.81)
SJC28, mean (SD) 9.6 (5.56)
DAS28–ESR n=3270
Moderate disease activity (3.2–5.1), n (%) 698 (21.3)
High disease activity (>5.1), n (%) 2572 (78.7)
Mean (SD) 5.97 (1.095)
DAS28–CRP n=3236
Mean (SD) 5.41 (0.998)
CRP (mg/l) n=3236
Mean (SD) 14.48 (20.376)
ESR (mm/h) n=3280
Mean (SD) 34.9 (24.64)
Anti-CCP n=3225
Continued
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treatment period (ﬁgure 3). At months 2, 4 and 6, patterns
similar to those observed with EULAR and DAS28–ESR
responses were seen for the percentage of patients with DAS28–
CRP low disease activity (24.54%, 38.66% and 49.51%,
respectively), DAS28–CRP remission (11.59%, 23.32% and
32.47%, respectively), SDAI low disease activity (20.46%,
36.74% and 48.32%, respectively), and SDAI remission
(2.68%, 8.69% and 14.15%, respectively).
HAQ–DI also improved throughout the 6 months of golimu-
mab treatment, with minimal or no functional impairment
(HAQ–DI ≤0.5) achieved in 26.37%, 33.14% and 37.38% of
patients at months 2, 4 and 6, respectively. Mean HAQ–DI
improved from 1.44 at baseline to 1.07, 0.94 and 0.88 at
months 2, 4 and 6, respectively.
Patients who had high disease activity at baseline were less
likely to achieve remission than patients who had moderate
disease activity at baseline (see supplementary ﬁgure S2, avail-
able online only), whether remission was measured by DAS28–
ESR, DAS28–CRP, or SDAI criteria. Patients with shorter
disease duration were somewhat more likely to attain remission.
Month 6 DAS–ESR remission rates were 27.81%, 24.48%,
22.11% and 21.00% in patients with disease durations of less
than 2 years, 2 to less than 5 years, 5–10 years and over
10 years, respectively (the only comparison that was statistically
signiﬁcant was the comparison between the shortest and the
longest duration groups, p=0.0339).
Patterns of EULAR response and DAS28–ESR remission were
very similar in patients who received only concomitant leﬂuno-
mide (the largest subgroup of patients who did not receive con-
comitant methotrexate; 9% of the population), and patients
who received any combination of concomitant DMARD that
included methotrexate (81% of the population). The response
patterns in both of these groups were similar to those of the
overall population (see supplementary ﬁgure S3, available online
only; baseline characteristics and safety data are shown in sup-
plementary tables S1 and S2, available online only).
Part 2
At the primary endpoints and all other time points in part 2,
the percentages of patients who achieved DAS28–ESR remis-
sion did not differ between the IV+SC and subcutaneous goli-
mumab groups (ﬁgure 4). Overall, approximately 25% of
patients achieved remission after the additional 6 months of
treatment.
The normalised AUC for DAS28–ESR between the end of
month 6 and end of month 12 was similar for the IV+SC
group (mean 3.67; SD 0.992) and the subcutaneous group
(mean 3.67; SD 0.924, p=0.931); differences in DAS28–ESR
Table 1 Continued
Patient characteristics: part 1 Subcutaneous golimumab (N=3280)
Positive, (≥20 U/ml), n (%) 2318 (71.9)
Rheumatoid factor n=3234
Positive (≥15 IU/ml), n (%) 2344 (72.5)
HAQ–DI, mean (SD) 1.44 (0.67)
N=490
Patient characteristics: part 2 IV+SC golimumab (N=242) Subcutaneous golimumab (N=248)
Demographic characteristics
Female, n (%) 211 (87.2) 211 (85.1)
Age, years
Mean (SD) 53.4 (12.65) 52.7 (12.77)
Race, n (%)
White 184 (76.0) 182 (73.4)
Multiracial 37 (15.3) 45 (18.1)
Other 7 (2.9) 9 (3.6)
Asian 5 (2.1) 6 (2.4)
Black or African American 3 (1.2) 2 (0.8)
American Indian or Alaska Native 1 (0.4) 0
Not allowed to collect data 5 (2.1) 4 (1.6)
BMI (kg/m2), median (min, max) 26.57 (16.6, 54.5) 26.76 (16.9, 52.3)
Disease characteristics Part 1 baseline Part 2 baseline† Part 1 baseline Part 2 baseline†
DAS28–ESR, mean (SD) 6.23 (1.008) 4.00 (0.810) 6.27 (1.003) 3.98 (0.834)
DAS28–CRP, mean (SD) 5.59 (0.956) 3.46 (0.822) 5.68 (0.963) 3.50 (0.837)
TJC28, mean (SD) 14.4 (6.66) 4.6 (3.89) 14.3 (6.97) 4.6 (4.08)
SJC28, mean (SD) 10.6 (5.31) 2.9 (2.93) 11.3 (5.78) 3.3 (3.06)
CRP (mg/l), mean (SD) 14.69 (19.591) 7.6 (13.371) 15.49 (23.622) 8.14 (18.048)
ESR (mm/h), mean (SD) 36.5 (24.17) 24.5 (18.30) 35.2 (22.97) 22.6 (17.02)
HAQ–DI, mean (SD) 1.52 (0.574) 0.92 (0.629) 1.57 (0.643) 0.96 (0.617)
*Each additional combination used by less than 3% of patients.
†Part 2 baseline measurements were those taken at the start of study month 7 (visit 6).
BMI, body mass index; CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, 28-joint disease activity score; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte
sedimentation rate; HAQ–DI, health assessment questionnaire–disability index; IV+SC, intravenous plus subcutaneous; max, maximum; min, minimum; SJC28, swollen joint count 28;
TJC28, tender joint count 28.
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were non-signiﬁcant at each time point during part 2 (all
p>0.113). The treatment groups did not differ in the time to
ﬁrst DAS–ESR remission; Kaplan–Meier estimates of the per-
centage of patients in remission at month 12 were 44.31% and
45.10% of patients for the IV+SC and subcutaneous golimu-
mab groups, respectively (p=0.791). Changes from baseline in
DAS28–ESR score, DAS28–CRP score, SDAI score and subcom-
ponents of these indices were similar across treatment regimens.
As observed in part 1, the responses of patients who received
concomitant methotrexate (77.1% of the part 2 population)
were similar to those of the full population (see supplementary
ﬁgure S4, available online only).
Safety results
Part 1
The most frequently reported TEAE in the safety population in
part 1 were nasopharyngitis (4.8%), urinary tract infection
(3.3%), headache (3.2%), diarrhoea (2.7%) and bronchitis
(2.4%). TEAE leading to early withdrawal occurred in 4.3%
(145/3357) of patients (upper section of table 2).
Serious TEAE occurred in 5.7% (190/3357) of patients in
part 1. The most common serious TEAE system organ class was
infections and infestations (58/3357, 1.7%), most commonly
pneumonia (0.27%), bacterial arthritis (0.15%), sepsis (0.12%)
and tuberculosis (0.12%).
Figure 2 Patient disposition. GLM, golimumab; IV, intravenous; SC, subcutaneous.
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Six deaths occurred during part 1, and four additional events
that led to death occurred in patients more than 30 days after
their last dose of study medication. Of the 10 deaths, ﬁve
were considered by the investigators to be potentially treatment
related (gastrointestinal haemorrhage, septic shock, multiple
myeloma, multiorgan failure, respiratory failure), and ﬁve were
classiﬁed as unrelated (cardiopulmonary failure, pancreatic carcin-
oma, cervix carcinoma, squamous cell carcinoma, metastatic
gastric cancer).
The incidence of clinically signiﬁcant abnormal laboratory
events was 4.9%, with the most common being elevation of
liver transaminases and anaemia. Injection site reactions
occurred in 0.7% of patients.
The subgroups of patients who received concomitant metho-
trexate (N=2656) or leﬂunomide only (N=309) had similar
percentages of patients with TEAE (54.93% vs 56.96%, respect-
ively), serious TEAE (5.12% vs 6.80%) and TEAE leading to
withdrawal (3.77% vs 6.80%) (see supplementary table S2,
available online only).
Part 2
The overall incidence of TEAE in part 2 was similar to that in
part 1 and similar across treatment groups (lower section of
table 2). The most frequently reported TEAE in the IV+SC
golimumab group were upper respiratory tract infection (6.1%
of patients), nasopharyngitis (5.3%) and diarrhoea (2.9%). In
the subcutaneous golimumab group, the most frequently
reported TEAE were nasopharyngitis (7.1%), urinary tract infec-
tion (3.9%), bronchitis (3.1%) and headache (3.1%). TEAE
leading to early withdrawal occurred in 4.9% and 2.4% of
patients in the IV+SC golimumab and subcutaneous golimumab
treatment arms, respectively. In the IV+SC golimumab group,
injection site pain occurred in one (0.4%) patient. No other
injection site or infusion reactions occurred in part 2.
Although the incidence of serious TEAE in part 2 was numer-
ically greater in the IV+SC golimumab group (6.9%; 17/245)
than in the subcutaneous golimumab group (2.4%; 6/255; lower
section of table 2), it was similar to that observed in part 1
(5.7%). The serious TEAE in the IV+SC group had no identiﬁ-
able pattern of system organ class distribution. The serious TEAE
that occurred in at least two patients in this group were pneumo-
nia and overdose (two each; 0.8%). The corresponding rates for
these events in the subcutaneous golimumab group were 0.4%
(one patient) for pneumonia and 0.4% (one patient) for over-
dose. All other serious TEAE occurred in one patient each.
Serious infections and infestations occurred in 2.0% (5/245)
and 0.8% (2/255) of patients in the IV+SC golimumab and sub-
cutaneous golimumab groups, with pneumonia occurring in two
(0.8%) and one (0.4%) patient, respectively. One death (0.4%
of patients) occurred in the IV+SC golimumab arm
Figure 3 Response to golimumab treatment over 6 months in part 1: percentage of patients with good or moderate EULAR response (A),a
percentage of patients who achieved good or moderate EULAR DAS28 response by the number of previously failed DMARDs (B), percentage of
patients who achieved good or moderate EULAR DAS28 response by concomitant methotrexate dose (C), and percentage of patients who achieved
low disease activity or remission (D).b DAS28, 28-joint disease activity score; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte
sedimentation rate; EULAR, European League Against Rheumatism; GLM, golimumab; MTX, methotrexate. aA good or moderate response was
deﬁned as DAS28–ESR improvement of more than 1.2 from any baseline score or an improvement of 0.6–1.2 from a baseline score of 5.1 or less.
bLow disease activity was deﬁned as DAS28–ESR of ≤3.2. Remission was deﬁned as DAS28–ESR of less than 2.6.
Figure 4 Percentage of patients with DAS28–ESR remission by
treatment group in part 2. DAS28, 28-joint disease activity score;
ESR, erythrocyte sedimentation rate; GLM, golimumab; IV, intravenous;
SC, subcutaneous.
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(cerebrovascular accident, considered by the investigator as
unlikely to have been treatment related).
Clinically signiﬁcant abnormal laboratory events occurred in
5.3% and 6.3% of patients in the IV+SC and subcutaneous
golimumab arms, respectively; the most common events were ele-
vation of liver transaminases and anaemia. No infusion-related
reactions occurred, and few injection-site reactions occurred
(IV+SC golimumab, 0.4%; subcutaneous golimumab, 0).
Table 2 Summary of patients with TEAE
Patients with TEAE* in part 1 Subcutaneous golimumab (N=3357), n (%)
One or more TEAE 1881 (56.0)
TEAE possibly or probably related to study medication 943 (28.1)
TEAE leading to early withdrawal 145 (4.3)
Deaths 6 (0.2)†
Injection site reactions 23 (0.7)
Clinically significant abnormal lab values 163 (4.9)
Serious TEAE 190 (5.7)
Infections and infestations 58 (1.7)
Injury, poisoning and procedural complications 26 (0.8)
Musculoskeletal and connective tissue disorders 25 (0.7)
Cardiac disorders 15 (0.4)
Neoplasms benign, malignant and unspecified (including cysts and polyps) 15 (0.4)
Respiratory, thoracic and mediastinal disorders 15 (0.4)
Gastrointestinal disorders 14 (0.4)
Nervous system disorders 11 (0.3)
General disorders and administration site conditions 10 (0.3)
Vascular disorders 9 (0.3)
Renal and urinary disorders 7 (0.2)
Metabolism and nutrition disorders 6 (0.2)
Hepatobiliary disorders 4 (0.1)
Skin and subcutaneous tissue disorders 4 (0.1)
Surgical and medical procedures 4 (0.1)
Blood and lymphatic system disorders 3 (0.1)
Immune system disorders 3 (0.1)
Investigations 3 (0.1)
Psychiatric disorders 3 (0.1)
Reproductive system and breast disorders 3 (0.1)
Eye disorders 2 (0.1)
Ear and labyrinth disorders 1 (0.03)
Patients with TEAE in part 2 IV+SC golimumab (N=245) n (%) Subcutaneous golimumab (N=255) n (%)
One or more TEAE 133 (54.3) 127 (49.8)
TEAE possibly or probably related to study medication 65 (26.5) 57 (22.4)
TEAE leading to early withdrawal 12 (4.9) 6 (2.4)
Deaths 1 (0.4) 0
Injection site reactions 1 (0.4) 0
Clinically significant abnormal lab values 13 (5.3) 16 (6.3)
Serious TEAE 17 (6.9) 6 (2.4)
Infections and infestations 5 (2.0) 2 (0.8)
Musculoskeletal and connective tissue disorders 3 (1.2) 0
Injury, poisoning, and procedural complications 3 (1.2) 1 (0.4)
Respiratory, thoracic and mediastinal disorders 2 (0.8) 0
Gastrointestinal disorders 2 (0.8) 0
Hepatobiliary disorders 1 (0.4) 0
General disorders and administration site conditions 1 (0.4) 0
Cardiac disorders 1 (0.4) 0
Neoplasms benign, malignant and unspecified 1 (0.4) 2 (0.8)
Nervous system disorders 1 (0.4) 0
Skin and subcutaneous tissue disorders 0 1 (0.4)
Investigations 0 1 (0.4)
*A TEAE was defined as an adverse event occurring during the treatment period if it started on or after the first dose of study medication, and up to 30 days after the last dose of
study medication, or if it was present before the first dose of study medication, but increased in severity during the treatment period.
†Four additional events that led to death occurred in patients more than 30 days after their last dose of study medication.
IV+SC, intravenous plus subcutaneous; TEAE, treatment-emergent adverse event.
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DISCUSSION
Of the 3280 efﬁcacy-evaluable patients in the GO-MORE study,
82.1% achieved good or moderate EULAR DAS28–ESR
response following 6 months of golimumab add-on treatment,
and 23.9% achieved DAS28–ESR remission. This remission rate
is similar to the rates reported in other observational studies of
TNF inhibitors (etanercept, inﬂiximab and adalimumab) in
patients with RA, which ranged from 8% to 28%.18–21 The
remission rate is also comparable to the ReAct study, which
investigated the efﬁcacy of adalimumab with or without con-
comitant DMARD (16% vs 20% at 3 months, respectively).22
The study population was typical of clinical practice settings,
and conﬁrms the beneﬁt of adding golimumab to conventional
DMARD therapy. Patients showed response to treatment as early
as the start of month 2 (after only one injection of subcutaneous
golimumab) and had steady improvement in several measures of
disease control over 6 months of treatment. EULAR response
was consistently achieved, regardless of the concomitant metho-
trexate dose, concomitant DMARD background, concomitant
corticosteroid use, or the number of previously failed DMARD.
Previous pivotal RA trials did not study the efﬁcacy and safety of
golimumab when used with background treatments other than
methotrexate.5 6 In the current study, patients had similar
response patterns whether they received golimumab with con-
comitant methotrexate or leﬂunomide. In addition, golimumab
efﬁcacy was not affected by the dose of concomitant methotrex-
ate. Similar results have been reported for certolizumab pegol
with concomitant methotrexate23 and adalimumab with con-
comitant methotrexate or with other DMARD.22
In part 2, to evaluate possible continuation treatment strategies
with golimumab, patients who responded but did not achieve
remission after 6 months of subcutaneous golimumab treatment
were eligible to receive an additional 6 months of treatment with
either a subcutaneous-only regimen or switch to a short-term
intravenous golimumab regimen to induce remission, followed
by subcutaneous golimumab. Both strategies were equally effect-
ive; each had a DAS28–ESR remission rate of approximately
25%. The reason for the similar responses between the treatment
groups remains unclear. The loss of the numerical difference
between the two treatment arms observed early in part 2 may
indicate that small improvements achieved with intravenous goli-
mumab should be maintained with intravenous golimumab
instead of resumed subcutaneous golimumab. This study did not
test this possibility. Another uninvestigated potential explanation
is that a plateau effect prevents increased intravenous golimumab
efﬁcacy despite greater peak concentrations.
In general, golimumab was well tolerated. The pattern of
TEAE was consistent with previous reports on golimumab and
other TNF antagonists in this population,10 11 24 with no new
signals identiﬁed. In this study, serious adverse event occurred in
a lower percentage of patients (5%) than previously observed in
a large, similarly designed study with the TNF antagonist adali-
mumab (13%); however, the three system organ classes with the
greatest number of serious TEAE (infections and infestations;
injury, poisoning and procedural complications; musculoskeletal
and connective tissue disorders) were the same between the
studies.22 In part 1, 0.7% of patients (26 patients) had a TEAE
in the ‘neoplasms benign, malignant, and unspeciﬁed’ category
and 0.4% of patients (15 patients) had a serious TEAE in this
category; in part 2, four of these events occurred, three of
which were serious. These rates are comparable to those
reported in a meta-analysis of randomised, controlled trials
in patients with RA; malignancies were reported in 0.7%
(123/15 989) of patients who received biological agents with
methotrexate and 0.6% (65/9,819) of patients who received
either placebo and/or any non-biological DMARD.25
In part 2, the percentage of patients with serious TEAE was
numerically greater in the IV+SC golimumab group (6.9%)
than the subcutaneous golimumab group (2.4%); however, the
percentage in the IV+SC group was comparable to the percent-
age for patients who had subcutaneous golimumab treatment in
part 1 (5.7%). This percentage is also similar to that observed in
the GO-FURTHER trial, in which patients with RA received a
combination of intravenous golimumab and methotrexate, and
4.1% of patients reported serious adverse events over
24 weeks.11 With other TNF inhibitors, serious infection risk
has been shown to decrease after 6 months of treatment.26 In
the current study, serious infections occurred in 1.7% of
patients at month 6. At month 12, the rate had increased to
2.0% in the IV+SC golimumab group and decreased to 0.8% in
the subcutaneous golimumab group.
One strength of the GO-MORE study is that the number of
enrolled patients was large enough to allow for comparison of
responses among various patient subpopulations and collection
of safety data on a broad sample of patients with RA. Although
the open-label, observational, non-randomised design of part 1
makes the study subject to certain biases, it is also beneﬁcial
because the data are likely to be representative of that obtained
in clinical practice.
Overall, the results from the GO-MORE study suggest that
adding golimumab to several different non-biological DMARD
has a favourable beneﬁt-to-risk proﬁle in a broader RA patient
population than was studied in previous clinical trials. In this
typical clinical practice population, approximately 80% of
patients achieved good or moderate EULAR response, and
approximately 25% achieved remission at month 6, regardless
of concomitant or previous DMARD treatment.
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